Par Pharmaceutical announced the launch of Candesartan Cilexetil/Hydrochlorothiazide Tablets, the generic version of AstraZeneca‘s Atacand HCT.

Atacand HCT is indicated for the treatment of hypertension and may be substituted for titrated components, but is not for initial therapy.  It is a combination of candesartan cilexetil, an angiotensin II receptor blocker, and hydrochlorothiazide, a diuretic.

Candesartan and Hydrochlorothiazide Tablets are available in 16mg/12.5mg, 32mg/12.5mg, and 32mg/25mg dosage strengths.  Par has begun shipment of these products.

For more information call (800) 828-9393 or visit